<DOC>
	<DOCNO>NCT00724295</DOCNO>
	<brief_summary>This post-marketing surveillance patient chronic hepatitis C treat PegIntron Rebetol combination therapy clinical practice Japan . The objective study evaluate safety efficacy combination therapy . The study also compare safety profile combination therapy among elderly patient young patient . Post-marketing survey consider applicable clinical trial thus result survey post conclusion . The result submit public health official require applicable national international law .</brief_summary>
	<brief_title>Safety Efficacy PegIntron Rebetol Combination Therapy Patients With Chronic Hepatitis C Japan ( Study P04505 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients chronic hepatitis C. Patients serogroup 1 ( genotype I ( 1a ) II ( 1b ) ) . The HCVRNA level blood 10^5 IU/mL RTPCR method , 1Meq./mL bDNA method Patients history hypersensitivity test drug interferon preparation Patients history hypersensitivity biological product , vaccine Patients treat Shosaikoto Patients autoimmune hepatitis Pregnant woman , woman may pregnant , nurse mother Patients history hypersensitivity component drug nucleoside analog ( aciclovir , ganciclovir , vidarabine , etc . ) Patients difficulttocontrol cardiac disease ( eg , myocardial infarction , cardiac failure , arrhythmia ) Patients hemoglobinopathy ( eg , thalassemia , sicklecell anemia ) Patients chronic renal failure renal function disorder creatinine clearance &lt; =50 mL/min Patients history severe psychiatric condition severe depression , suicidal ideation suicide attempt Patients serious hepatic dysfunction Patients autoimmune hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>